Editas Medicine, Inc

(NASDAQ:EDIT)

Created with Raphaël 2.1.21330-100100
STRONG BUY

Latest On Editas Medicine, Inc (EDIT):

About Editas Medicine, Inc (EDIT):

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is develo read more...ping gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

See Advanced Chart

General

  • Name Editas Medicine, Inc
  • Symbol EDIT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 235
  • Fiscal Year EndDecember
  • IPO Date2016-02-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.editasmedicine.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 26.85
  • Price/Book (Most Recent Quarter) 6.25
  • Enterprise Value Revenue 25.23
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.34
  • Next Year EPS Estimate -$3.49
  • Next Quarter EPS Estimate -$0.78
  • Profit Margin -128%
  • Operating Margin -149%
  • Return on Assets -16%
  • Return on Equity -35%
  • Revenue 90.73 million
  • Earnings Per Share -$2.14
  • Revenue Per Share $1.55
  • Gross Profit -67264000
  • Quarterly Earnings Growth -7%
View More

Highlights

  • Market Capitalization 2.91 billion
  • EBITDA -106383000
  • PE Ratio -1.59
  • Analyst Target Price $52.83
  • Book Value Per Share $6.29
View More

Share Statistics

  • Shares Outstanding 67.36 million
  • Shares Float 66.37 million
  • % Held by Insiders 137%
  • % Held by Institutions 82.21%
  • Shares Short 11.31 million
  • Shares Short Prior Month 9.84 million
  • Short Ratio 4.22
  • Short % of Float 17%
  • Short % of Shares Outstanding 17%
View More

Technicals

  • Beta 2.08
  • 52 Week High $99.95
  • 52 Week Low $18.2
  • 50 Day Moving Average 52.94
  • 200 Day Moving Average 46.49
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Editas Medicine, Inc (EDIT) Dividend Calendar:

Editas Medicine, Inc (EDIT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Editas Medicine, Inc (EDIT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Editas Medicine, Inc (EDIT) Chart:

Editas Medicine, Inc (EDIT) News:

Below you will find a list of latest news for Editas Medicine, Inc (EDIT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Editas Medicine, Inc (EDIT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Latest EDIT Trades:

Editas Medicine, Inc (EDIT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Editas Medicine, Inc (EDIT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Editas Medicine, Inc (EDIT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 137%
Institutional Ownership: 8221%